Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

[Figure: see text]

Detalles Bibliográficos
Autores principales: Cantini, Fabrizio, Niccoli, Laura, Matarrese, Daniela, Nicastri, Emanuele, Stobbione, Paolo, Goletti, Delia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Infection Association. Published by Elsevier Ltd. 2020
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177073/
https://www.ncbi.nlm.nih.gov/pubmed/32333918
http://dx.doi.org/10.1016/j.jinf.2020.04.017
_version_ 1783525139819790336
author Cantini, Fabrizio
Niccoli, Laura
Matarrese, Daniela
Nicastri, Emanuele
Stobbione, Paolo
Goletti, Delia
author_facet Cantini, Fabrizio
Niccoli, Laura
Matarrese, Daniela
Nicastri, Emanuele
Stobbione, Paolo
Goletti, Delia
author_sort Cantini, Fabrizio
collection PubMed
description [Figure: see text]
format Online
Article
Text
id pubmed-7177073
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The British Infection Association. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71770732020-04-23 Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact Cantini, Fabrizio Niccoli, Laura Matarrese, Daniela Nicastri, Emanuele Stobbione, Paolo Goletti, Delia J Infect Letters to the Editor [Figure: see text] The British Infection Association. Published by Elsevier Ltd. 2020-08 2020-04-23 /pmc/articles/PMC7177073/ /pubmed/32333918 http://dx.doi.org/10.1016/j.jinf.2020.04.017 Text en © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letters to the Editor
Cantini, Fabrizio
Niccoli, Laura
Matarrese, Daniela
Nicastri, Emanuele
Stobbione, Paolo
Goletti, Delia
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
title Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
title_full Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
title_fullStr Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
title_full_unstemmed Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
title_short Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
title_sort baricitinib therapy in covid-19: a pilot study on safety and clinical impact
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177073/
https://www.ncbi.nlm.nih.gov/pubmed/32333918
http://dx.doi.org/10.1016/j.jinf.2020.04.017
work_keys_str_mv AT cantinifabrizio baricitinibtherapyincovid19apilotstudyonsafetyandclinicalimpact
AT niccolilaura baricitinibtherapyincovid19apilotstudyonsafetyandclinicalimpact
AT matarresedaniela baricitinibtherapyincovid19apilotstudyonsafetyandclinicalimpact
AT nicastriemanuele baricitinibtherapyincovid19apilotstudyonsafetyandclinicalimpact
AT stobbionepaolo baricitinibtherapyincovid19apilotstudyonsafetyandclinicalimpact
AT golettidelia baricitinibtherapyincovid19apilotstudyonsafetyandclinicalimpact

Ejemplares similares